SLC2A4 and metabolic syndrome: In this context, LASSBio-1986 increased insulin sensitivity, enhanced GLUT-4 expression in skeletal muscle and attenuated dexamethasone-induced dyslipidemia, again underscoring the advantage of a multimodal profile.